In 2012, researchers analysed a commercial formulation labelled TB-500. They identified a seven-amino-acid segment corresponding to positions 17–23 of thymosin beta-4, with an acetyl group at one end. That fragment is smaller than the full thymosin beta-4 molecule.1
The finding describes the formulation examined in that paper. It does not establish the identity of every product bearing the name. Matching research to a catalogue item requires documentation of that item's molecular identity; a shared label is insufficient.1











